Can Lamotrigine (lamotrigine) cause lymphadenopathy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Lamotrigine Cause Lymphadenopathy?

Yes, lamotrigine can cause lymphadenopathy, though it is a rare adverse effect that typically occurs as part of a hypersensitivity syndrome or drug reaction with eosinophilia and systemic symptoms (DRESS).

Clinical Presentation and Timing

Lymphadenopathy associated with lamotrigine typically presents within specific timeframes and clinical contexts:

  • Onset occurs within 6-24 days following treatment initiation, often accompanied by other systemic symptoms 1
  • The lymphadenopathy commonly presents with fever, rash, and cytopenia as part of a broader hypersensitivity reaction 2, 1
  • Swollen lymph nodes may appear even after the last dose of lamotrigine has been administered, making temporal relationships less obvious 3

Associated Clinical Syndromes

The lymphadenopathy rarely occurs in isolation and is typically part of more serious systemic reactions:

  • Drug-induced hypersensitivity syndrome (DHS/DRESS) is the most common presentation, featuring rash, lymphadenopathy, liver enzyme abnormalities, and fever 2
  • Haemophagocytic lymphohistiocytosis (HLH) represents a potentially life-threatening complication, with major features including fever, cytopenia, rash, hyperferritinaemia, and lymphadenopathy 1
  • Isolated lymphadenopathy has been documented in case reports, though this presentation is less common 4, 5

Risk Factors and Drug Interactions

Certain clinical scenarios increase the risk of lamotrigine-induced lymphadenopathy:

  • Concomitant use with valproic acid significantly increases risk due to elevated lamotrigine levels and enhanced toxicity potential 3, 6
  • Exceeding recommended initial dosage is a documented risk factor for serious adverse reactions including hypersensitivity syndromes 6
  • Patients with documented allergies to structurally similar anticonvulsants (phenytoin, carbamazepine, phenobarbital) may be at higher risk, as lamotrigine shares an aromatic ring structure with these medications 5

Monitoring and Management

When lymphadenopathy develops in patients taking lamotrigine:

  • Immediate discontinuation of lamotrigine is essential when signs of hypersensitivity appear, with 15 of 17 reported HLH cases improving after drug withdrawal 1
  • If valproic acid is co-administered, both medications should be withdrawn early when hypersensitivity signs emerge 3
  • Glucocorticoid treatment may be necessary for managing severe reactions with progressive symptoms 3
  • Baseline laboratory monitoring should include complete blood count, liver function tests, and renal function tests before initiating therapy 6

Important Clinical Caveats

  • The rarity of this adverse effect (only a handful of cases reported over 20+ years) means it may not be on most clinicians' differential diagnosis for lymphadenopathy 4
  • Mortality can occur: 2 of 17 patients with lamotrigine-induced HLH died despite intervention 1
  • Progressive symptoms may continue for several days after drug discontinuation before improvement begins 3
  • Patients should be counseled to seek immediate medical attention if they develop fever, rash, or swollen lymph nodes while taking lamotrigine 1

References

Research

Lamotrigine hypersensitivity syndrome and spiking Fever.

Indian journal of dermatology, 2012

Research

Lamotrigine induced lymphadenopathy: Case report and literature review.

International journal of pediatric otorhinolaryngology, 2017

Research

Lymphadenopathy secondary to lamotrigine (Lamictal).

Veterinary and human toxicology, 2002

Guideline

Lamotrigine Dosage and Administration

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.